Abstracts tagged "Bisphosphonates"

Abstract Number: 2059 • 2012 ACR/ARHP Annual Meeting
The Efficacy of Clinical Guidelines in Promoting Co-Prescription of Bone Protection with Glucocorticoids Among Hospital Doctors Treating Inpatients
Leonard C. Harty¹, James Clare², Dylan Finnerty², Susan Van Der Kamp², Fionnuala Kennedy³, Malachi McKenna⁴ and Oliver M. FitzGerald¹, ¹Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ²Department of Rheumatology, St. Vincent's University Hospital, Dublin, Ireland, ³Pharmacy Department, St. Vincent's University Hospital, Dublin, Ireland, ⁴Department of Endocrinology & Metabolic Bone Disease, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: Therapeutic glucocorticoids (GC) rapidly decrease bone mineral density, inducing a remodelling imbalance by promoting osteoclast differentiation and activation and by inhibiting oscteocytes. Current guidelines…
Abstract Number: 1971 • 2012 ACR/ARHP Annual Meeting
Resolution of Effects On Bone Turnover Markers and Bone Mineral Density After Discontinuation of Long-Term Bisphosphonate Use
Kenneth G. Saag¹, Claude-Laurent Benhamou², Tobias De Villiers³, C. Conrad Johnston Jr.⁴, Bente Langdahl⁵, Andrew Denker⁶, Annpey Pong⁶, John P. McGinnis⁶, Elizabeth Rosenberg⁶ and Arthur Santora⁶, ¹Div Clinical Immun & Rheum, Univ of Alabama-Birmingham, Birmingham, AL, ²Centre Hospitalier Régional d'Orléans, Orleans, France, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Indiana University School of Medicine, Indianapolis, IN, ⁵Aarhus University Hospital, Aarhus, Denmark, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ
Background/Purpose: While bisphosphonates (BP) have been well studied in long-term trials of up to 4 years' duration, relatively less is known about the immediate consequences…
Abstract Number: 1974 • 2012 ACR/ARHP Annual Meeting
Incidence of Atypical Femur Fractures Associated with Bisphosphonate Use for Osteoporosis: A Systematic Review of the Literature
John N. Mecchella¹, John A. Batsis², Robin J. Larson³ and Gautham Suresh⁴, ¹Rheumatology, Dartmouth Hitchcock Medical Center, Lebanon, NH, ²General Internal Medicine, Dartmouth Hitchcock Medical Center, Lebanon, NH, ³The Dartmouth Institute for Health Policy and Clinical Practice, Lebanon, NH, ⁴Neonatology, Pediatrics, Dartmouth Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Reports of a link between bisphosphonate use in patients with osteoporosis and atypical femoral fractures--those occurring in subtrochanteric or diaphyseal locations--have generated significant concern…
Abstract Number: 727 • 2012 ACR/ARHP Annual Meeting
Effects of Odanacatib On BMD and Overall Safety in the Treatment of Osteoporosis in Postmenopausal Women Previously Treated with Alendronate
Roland Chapurlat¹, Sydney Bonnick², Tobias De Villiers³, Alberto Odio⁴, Santiago Palacios⁵, Boyd Scott⁶, Celine Le Bailly De Tilleghem⁷, Carolyn DaSilva⁶, Albert Leung⁸ and Deborah Gurner⁶, ¹Hôpital Edouard Herriot, Lyon, France, ²Director Osteoporosis Services, Cooper Clinic, Dallas, TX, ³Mediclinic Panorama and Department of Obstetrics & Gynecology, University of Stellenbosch, Cape Town, South Africa, ⁴Alta California Medical Group, Simi Valley, CA, ⁵Instituto Palacios, Madrid, Spain, ⁶Merck Sharp & Dohme Corp., Whitehouse Station, NJ, ⁷MSD Europe Inc., Brussels, Belgium, ⁸Clinical Research, Merck Sharp and Dohme Corp., Rahway, NJ
Background/Purpose: Odanacatib (ODN) is a potent, orally-active cathepsin K inhibitor being developed for the treatment of postmenopausal osteoporosis. This study evaluated the effects of ODN…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].